<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04013048</url>
  </required_header>
  <id_info>
    <org_study_id>FZPL-I-107</org_study_id>
    <nct_id>NCT04013048</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor</brief_title>
  <official_title>A Phase I Mass Balance and Biotransformation Study of [14C]-Fluzoparib in Chinese Patients With Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Evaluate the Mass Balance and Biotransformation of Single Dose [14C]-FZPL in Chinese&#xD;
      Patients with Solid Tumor&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Actual">December 24, 2019</completion_date>
  <primary_completion_date type="Actual">December 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The distribution of Fluzoparib in the whole blood and plasma and whole.radioactive pharmacokinetics following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled Fluzoparib recovered in blood and in total, up to Day 10 (approx).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of whole radioactivity of excrement of orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor to obtain the mass balance data and the main excretion pathway in human body.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled Fluzoparib recovered in urine, faeces and in total, up to Day 10 (approx).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of the main metabolite and biotransformation pathway of Fluzoparib and investigation of metabolite with proportion &gt;10% in plasma following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>Proportion of different metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of the concentrations of Fluzoparib in plasma using the validated LC-MS/MS to obtain pharmacokinetic data.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>The concentrations of Fluzoparib in plasma up to Day 10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observation of safety following the single orally administered [14C]-Fluzoparib in Chinese patients with advanced solid tumor.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>Adverse events assessed by CTCAE v5.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>[14C]-Fluzoparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive single dose of [14C]- Fluzoparib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-Fluzoparib</intervention_name>
    <description>Patients will receive single dose of orally [14C]- Fluzoparib on Day 1.</description>
    <arm_group_label>[14C]-Fluzoparib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects diagnosed with advanced solid malignancies who are refractory or intolerant&#xD;
             to standard therapy or considered to be benefit from the treatment of fluzoparib.&#xD;
&#xD;
          2. ECOG performance status of 0 to 1.&#xD;
&#xD;
          3. Life expectancy of more than 3 months.&#xD;
&#xD;
          4. Signing the informed consent forms.&#xD;
&#xD;
          5. Adequate bone marrow, liver and renal function.&#xD;
&#xD;
          6. Be able to communicate well with the researcher and be able to complete the trial in&#xD;
             accordance with the program.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who take any drugs that strongly inhibit or induce the CYP450 enzyme 14 days&#xD;
             prior to study drug administration；&#xD;
&#xD;
          2. Those who have history of alcohol abuse (it was defined as that the daily alcohol&#xD;
             consumption was higher than the following criteria: the weekly alcohol consumption was&#xD;
             higher than 14 units of alcohol (1 unit= 360 ml beers/45 ml liquor containing 40%&#xD;
             alcohol/150ml grape wine) 6 months prior to screening period, or the alcohol breath&#xD;
             test results ≥20 mg/dl during screening period；&#xD;
&#xD;
          3. Subjects who smoked daily &gt;5 sticks of cigarette 3 months prior to first dose or&#xD;
             cannot give up smoking during study.&#xD;
&#xD;
          4. Subjects who have history of drug abuse or taking soft drug (i.e., marihuana) 3 months&#xD;
             prior to screening period or taking hard drugs (i.e., cocaine, amphetamines,&#xD;
             benzodiazepine, etc.); or the results of urine test in drugs were positive.&#xD;
&#xD;
          5. Subjects who were used to drink grapefruit juice or overconsumption of tea, coffee,&#xD;
             and the drink with caffeine; and cannot give up them during test.&#xD;
&#xD;
          6. Subjects who need long-term exposure to radiation, or who have been exposed to PET-CT&#xD;
             or ECT within 3 months prior to study drug administration or who have participated in&#xD;
             the labeling test of radiopharmaceuticals.&#xD;
&#xD;
          7. Subjects who have fertility planning within the range of starting trial - 1 year after&#xD;
             finishing trial.&#xD;
&#xD;
          8. Subjects who have excessive bleeding or blood donation (400ml) 3 months prior to&#xD;
             screening period, or planned to donate blood 1 month after finishing this trial.&#xD;
&#xD;
          9. Subjects who have habitual constipation or diarrhea, irritable bowel syndrome,&#xD;
             inflammatory bowel disease.&#xD;
&#xD;
         10. Subjects must not have had prior treatment with PARP inhibitors.&#xD;
&#xD;
         11. Subjects who cannot complete this study because of other reasons, or any factors&#xD;
             judged by investigator that the participants cannot meet.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 7, 2019</study_first_submitted>
  <study_first_submitted_qc>July 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <keyword>14C-Fluzoparib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

